Hayley Virgil is a senior editor with CancerNetwork. When she isn't traveling to conferences and championing health equity in the oncology space, she can be found hiking, foraging wild plants, gardening, sewing ballgowns, practicing embroidery, or playing video games.
Endometriosis/Adenomyosis Status Not an Independent Predictor of Survival in Endometrial Cancer
April 9th 2022Although patients with endometrial cancer who had histologically confirmed endometriosis/adenomyosis achieved better overall survival than those without, the benefit was linked to stage, grade, age, and histological subtype.
HER2+ Apocrine Carcinoma of the Breast Trends Towards Less Aggressive Phenotype, Favorable Outcomes
April 7th 2022Patients with HER2-positive apocrine carcinoma of the breast are less likely to have an aggressive phenotype and are more likely to have favorable outcomes, even though the group has a lower rate of estrogen and progesterone receptor positivity.
FDA Places Partial Clinical Hold on Phase 1/2 Emavusertib Study in R/R AML, High-Risk MDS
April 6th 2022The phase 1/2a TakeAim Leukemia trial assessing emavusertib alone or with azacitidine or venetoclax in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome has been placed on a partial clinical hold by the FDA.
First-Line Tiragolumab Combo Misses PFS Co-Primary End Point in ES-SCLC
April 2nd 2022Although tiragolumab plus atezolizumab and chemotherapy missed the primary end point of progression-free survival superiority in the phase 3 SKYSCRAPER-02 trial in patients with extensive-stage small cell lung cancer, it will continue to be evaluated in non–small cell lung cancer.
Rachel Pearlman, MS, LGC, Discusses Fine Tuning Genetic/Germline Testing for CRC
March 30th 2022In an interview with CancerNetwork® during National Colorectal Cancer Awareness Month, Rachel Pearlman, MS, LGC, highlights recent updates in genetic testing in colorectal cancer and where the field needs to head to provide individuals with better options.
Proposed Legislation Could Put Expiration Date on Accelerated Approvals
March 22nd 2022Maurie Markman, MD, sits down with CancerNetwork® to discuss proposed legislation that would put a time limit on how long drugs with an accelerated approval can stay on the market, and how that may negatively impact patients with cancer.
Adjuvant Pembrolizumab Significantly Improved DMFS Vs Placebo in Resected Stage IIB/C Melanoma
March 8th 2022The phase KEYNOTE-716 trial, which assessed the use of adjuvant pembrolizumab in patients with resected stage IIB and IIC melanoma, met its secondary end point of distant metastasis-free survival.
CYAD-101 CRC Trial Receives Clinical Hold Following Discussion With FDA
March 4th 2022A clinical hold has been placed on the phase 1b CYAD-101-002 trial, examining pembrolizumab after treatment with CYAD-101 and folinic acid, fluorouracil, and oxaliplatin preconditioning in metastatic colorectal cancer.